CA Patent

CA2616112A1 — Oral suspension of prednisolone acetate

Assigned to TARO PHARMACEUTICALS NORTH AMERICA Inc · Expires 2007-02-15 · 19y expired

What this patent protects

The present invention relates to novel oral suspension formulation comprising prednisolone acetate, a pharmaceutically acceptable vehicle and a thickening agent. The present invention further provides a method of treating patients in need of prednisolone with the novel formulatio…

USPTO Abstract

The present invention relates to novel oral suspension formulation comprising prednisolone acetate, a pharmaceutically acceptable vehicle and a thickening agent. The present invention further provides a method of treating patients in need of prednisolone with the novel formulation.

Drugs covered by this patent

Patent Metadata

Patent number
CA2616112A1
Jurisdiction
CA
Classification
—
Expires
2007-02-15
Drug substance claim
No
Drug product claim
No
Assignee
TARO PHARMACEUTICALS NORTH AMERICA Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.